Literature DB >> 15343517

Silent corticotroph adenomas: further clinical and pathological observations.

John A Lopez1, B k Kleinschmidt-Demasters Bk, Chun-I Sze, Whitney W Woodmansee, Kevin O Lillehei.   

Abstract

Adrenocorticotroph cell pituitary adenomas immunoreactive for adrenocorticotropic hormone (ACTH) but unassociated with preoperative signs of hypercortisolism constitute between 6% and 43% of all ACTH adenomas. Few large series have been published. At our referral center for pituitary diseases, we have encountered 12 patients with silent ACTH adenomas, none of whom exhibited definite clinical features of hypercortisolism preoperatively. Two patients presented with apoplexy, and in 2 patients preoperative neuroimaging studies mimicked craniopharyngioma. Pathological examination revealed 8 adenomas with variably basophilic cytoplasm (type I, including 1 each with coarse basophilic granules and Crooke's hyaline change) and 4 with predominantly chromophobic cytoplasm (type II). Diffuse versus patchy (30% to 50% of cells) immunostaining best distinguished these 2 types; calcitonin staining was focal or negative in both. Two patients had unexpected postoperative courses consistent with acute cortisol insufficiency; 1 patient suffered from a severe flu-like illness, and the other had dizziness and was found to have a serum cortisol level of < 1.0 microg/dL. Both patients improved after cortisol replacement followed by a slow taper. Another patient developed 2 separate pituitary adenomas, a silent ACTH adenoma followed by a pure prolactinoma resected months later. Clonality studies demonstrated that the 2 tumors had arisen from different clonal populations. These cases offer additional insights into clinical, neuroimaging, histological, and biological features of silent ACTH adenomas. Because 2 of these patients seemed to require postoperative cortisol supplementation that otherwise would not have been given, clinicians should be notified about ACTH immunostaining in adenomas from patients without preoperative diagnoses of Cushing's disease, to optimize postoperative care.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15343517     DOI: 10.1016/j.humpath.2004.04.016

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  15 in total

Review 1.  Subclinical hyperfunctioning pituitary adenomas: the silent tumors.

Authors:  Odelia Cooper; Shlomo Melmed
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-05-22       Impact factor: 4.690

Review 2.  Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Chris G Yedinak; Isabelle Cetas; Shirley McCartney; Justin Cetas; Aclan Dogan; Maria Fleseriu
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

3.  An unusual manifestation of olfactory neuroblastoma.

Authors:  Zona Batacchi; Nicole K Andeen; Subbulaxmi Trikudanathan
Journal:  BMJ Case Rep       Date:  2018-03-13

4.  Symptomatic cystic degeneration of a clinically silent corticotroph tumor of the pituitary gland.

Authors:  Michael T Walsh; William T Couldwell
Journal:  Skull Base       Date:  2010-09

Review 5.  Silent (clinically nonfunctioning) pituitary adenomas.

Authors:  Sarah E Mayson; Peter J Snyder
Journal:  J Neurooncol       Date:  2014-03-28       Impact factor: 4.130

Review 6.  Silent corticotroph adenomas.

Authors:  Odelia Cooper
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

7.  The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas.

Authors:  Ozgur Mete; Caroline Hayhurst; Hussein Alahmadi; Eric Monsalves; Hasan Gucer; Fred Gentili; Shereen Ezzat; Sylvia L Asa; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

Review 8.  Modification of hormonal secretion in clinically silent pituitary adenomas.

Authors:  Tania Daems; Johan Verhelst; Alex Michotte; Pascale Abrams; Dirk De Ridder; Roger Abs
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

9.  Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas.

Authors:  Ozgur Mete; Karen Gomez-Hernandez; Walter Kucharczyk; Rowena Ridout; Gelareh Zadeh; Fred Gentili; Shereen Ezzat; Sylvia L Asa
Journal:  Mod Pathol       Date:  2016-01-08       Impact factor: 7.842

10.  Immunohistochemical properties of silent corticotroph adenoma and Cushing's disease.

Authors:  Kazumi Iino; Yutaka Oki; Fumie Matsushita; Miho Yamashita; Chiga Hayashi; Katsutoshi Miura; Shigeru Nishizawa; Hirotoshi Nakamura
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.